Qilu Pharmaceutical Unveils Promising Data for QL1706 in Cervical Cancer Treatment at ESMO 2023
China’s Qilu Pharmaceutical showcased compelling data for its combination drug QL1706 (iparomlimab and tuvonralimab) as...
Medytox Shifts Strategy for China Market Entry with Next-Generation Botulinum Toxin
Korea-based biopharmaceutical company Medytox has reportedly revamped its strategy for entering the Chinese market, according...
MicroPort MedBot’s Toumai Robot Gains NMPA Approval for Endoscopic Surgery
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252), a leading medical robotics company, has announced...
Danaher Corporation Reports Q3 2023 Earnings with 10.5% Global Revenue Decline
US-based science and tech services giant Danaher Corporation (NYSE: DHR) has reported its Q3 2023...
AstraZeneca Licenses Nanoform’s Starmap AI Platform to Enhance Drug Development
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has obtained a license from Finnish drug design...
EC Approves AstraZeneca and Daiichi Sankyo’s Enhertu for Advanced HER2+ NSCLC
The European Commission (EC) has granted registration approval for the HER2-directed antibody-drug conjugate (ADC) Enhertu...
Dizal’s Sunvozertinib Shows Promising Efficacy in Advanced NSCLC at ESMO 2023
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented compelling efficacy and safety data for its...
AbbVie Partners with Lupus Therapeutics to Advance Rinvoq in SLE Treatment
AbbVie (NYSE: ABBV) announced this week a strategic collaboration with US-based Lupus Therapeutics aimed at...
BMS’s BMS-986278 Receives FDA Breakthrough Therapy Designation for Pulmonary Fibrosis
Bristol-Myers Squibb (BMS; NYSE: BMY) announced this week that it has received breakthrough therapy designation...
Novartis Q3 Earnings Reflect Strong Growth Post-Sandoz Spinoff
Novartis (NYSE: NVS) has released its Q3 2023 financial results, marking the first report since...
Fosun Pharma Gains NMPA Approval for Phase I Trial of XS-03 in Advanced Solid Tumors
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a leading healthcare conglomerate in China, has...
Cutia Therapeutics’ CU-20401 Completes Phase I Study for Obesity Treatment
China-based dermatology specialist Cutia Therapeutics (HKG: 2487) has announced the last subject out (LSO) in...
Peking University Unveils National Standardized Pain Treatment Center in China
Peking University People’s Hospital has officially unveiled the plaque for the National Standardized Pain Treatment...
Leadinno Medical Valley Secures Series A+ Funding for Neuroregulation Device R&D
Leadinno Medical Valley, a Beijing-based innovator in pain management and neuroregulation devices, has reportedly secured...
China Grand Pharma Initiates Phase III Trial for GPN00833 in Cataract Surgery Recovery
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced a significant milestone...
Gates Foundation Funds CanSino’s Innovative Polio Vaccine Development
The Bill & Melinda Gates Foundation has announced a commitment of USD 2 million to...
OrbiMed Raises Over USD 4.3 Billion for Private Investment Funds Focused on Healthcare
US-based investment fund giant OrbiMed has announced the successful raising of over USD 4.3 billion...
BMS Regains Full Rights to Mavacamten in China and Asia from LianBio
Bristol-Myers Squibb (BMS; NYSE: BMY) is set to regain full control of mavacamten, a treatment...
Sihuan Pharmaceutical Gains NMPA Approval for Innovative Type 2 Diabetes Treatment
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that it has received clinical...
Jiangsu Aidea’s HIV-1 Drug ACC017 Accepted for NMPA Review in China
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced that the National Medical Products...